Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease (AD), is associated with behavioral disturbances in approximately 50% of
AD patients in Beijing. Agitation, and aggression specifically, is considered the most
serious noncognitive symptom experienced in patients with dementia. Memantine is a recognized
treatment for Alzheimer's disease either alone or in combination with cholinesterase
inhibitors. Its efficacy in vascular dementia is also established. Family members continue to
play a central role in home care for the demented elderly in China. This proposal is to
conduct a study in Beijing, China to investigate the efficacy and safety of Memantine in the
treatment of agitation and aggression in AD patients. In addition, this proposal aims to
explore the impact of memantine on caregiver burden of AD patients in Chinese culture.